查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018510

緩釋皮下胰島素輸注市場：依產品類型、胰島素類型、年齡層及最終用戶分類－2026年至2032年全球市場預測

Continuous Subcutaneous Insulin Infusion Market by Product Type, Insulin Type, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，緩釋皮下胰島素輸注市場價值將達到 34.1 億美元，到 2026 年將成長至 38.1 億美元，到 2032 年將達到 78.4 億美元，複合年成長率為 12.62%。

主要市場統計數據
基準年 2025 34.1億美元
預計年份：2026年 38.1億美元
預測年份 2032 78.4億美元
複合年成長率 (%) 12.62%

不斷變化的臨床重點和技術進步如何重塑持續胰島素輸注，使其朝著以患者為中心、互聯互通的治療解決方案發展。

在技​​術創新和護理模式轉移的雙重推動下，持續皮下胰島素輸注已從一種小眾臨床干預措施發展成為糖尿病治療的核心治療方法。現代系統優先考慮以患者為中心的功能，例如易用性、與血糖監測工具的整合以及符合人體工學的設計。隨著臨床醫生強調個人化血糖管理，設備開發商也積極回應，提供更精密的給藥機制、更直覺的使用者介面以及支援遠端監測和遠端保健工作流程的連接功能。

新的數位化整合、自適應控制演算法和供應鏈現代化正在迅速改變胰島素幫浦治療和護理服務模式。

皮下持續胰島素輸注技術的最新變化反映了數位醫療、設備小型化和整合式醫療模式的融合，這些變革共同重新定義了人們對治療的預期。感測器精確度的提高和複雜演算法的改進，使得胰島素給藥決策更加智慧，能夠適應活動量、飲食和壓力等現實生活中的波動。因此，產品藍圖優先考慮封閉回路型相容性、自適應控制策略和安全的資料交換，以支援長期照護管理。

2025 年貿易政策的轉變迫使所有參與胰島素治療的相關人員靈活地重新設計其供應鏈，應對關稅問題，並採取策略性的商業性應對措施。

2025年關稅徵收和貿易政策調整將對持續皮下胰島素輸注領域的製造商、經銷商和醫療保健服務提供者產生明顯的營運和策略影響。採購團隊需要重新評估籌資策略，以降低接收成本增加和前置作業時間的風險。為此，各公司正在探索替代製造地、將零件外包到近岸地區，並重新談判供應商契約，以分散關稅對整個供應鏈的影響。

從產品架構、胰島素配方、患者年齡層和護理環境等方面進行多方面的細分，揭示了採用促進因素和設計要求的差異。

嚴謹的細分觀點闡明了產品設計、胰島素製劑、患者族群特徵和醫療環境如何影響持續輸註解決方案的整體部署和使用者體驗。按產品類型分析揭示了傳統系統和貼片裝置之間的差異如何影響臨床適用性和患者偏好。傳統系統可進一步分為電子泵浦和機械泵浦。電子泵平台提供可程式設計的給藥模式、連接功能和先進的安全聯鎖裝置，而機械泵則在特定應用場景中優先考慮簡單性和耐用性。就胰島素類型而言，速效胰島素類似物、常規胰島素和短效製劑之間的選擇會影響動態特徵和給藥演算法，這既反映了設備編程，也反映了臨床劑量調整策略。

美洲、歐洲、中東和非洲以及亞太地區的區域差異，需要對監管、償還和商業化方法進行個別調整。

區域趨勢對持續輸注技術的應用路徑、報銷架構和基礎設施建設有顯著影響。在美洲，持續輸注技術的應用在不同的醫療保健系統和支付模式下呈現出多樣化的分佈，而那些整合醫療網路和糖尿病管理項目優先考慮互聯解決方案的地區，則出現了更先進的部署。因此，製造商正在調整其臨床合作和分銷策略，以適應區域報銷政策和專業培訓計畫。

競爭格局由傳統醫療設備製造商、軟體主導的新參與企業以及以結果主導的服務模式共同塑造，這些模式重新定義了整個治療生命週期的價值。

競爭格局由成熟的醫療設備製造商、新興技術參與企業和專業組件供應商組成，各方攜手合作，致力於提升持續輸注技術的效能。現有製造商憑藉著深厚的臨床關係、豐富的監管合規經驗和廣泛的分銷網路，維持著市場地位；而新參與企業則往往側重於軟體創新、用戶體驗和針對特定患者群體的利基外形規格。醫療設備製造商與數位醫療供應商之間的策略合作正在加速功能整合，尤其是在閉合迴路相容性和數據分析服務等領域。

我們將優先考慮互通性、多樣化的資料來源、真實世界的資料和人性化的設計，從而增強韌性並加快在所有醫療保健環境中的部署。

產業領導者應優先考慮將產品創新與臨床整合、供應鏈韌性和支付方合作相結合的策略議程，以維持永續性並加速產品普及。首先，投資可互通的平台和檢驗的演算法，以實現與血糖監測系統和電子健康記錄 (EHR) 的有效數據交換。這項基礎將支持臨床醫師的工作流程，並提升治療數據的臨床效用。其次，實現生產和籌資策略多元化，以減輕貿易政策波動和零件短缺的影響，並在發生中斷時縮短復原時間。

一個透明的混合方法研究框架，結合相關人員訪談、臨床文獻整合和供應鏈分析，產生可操作的醫療設備和商業性見解。

本研究途徑融合了定性和定量方法，旨在全面了解醫療設備的性能、相關人員的觀點以及營運限制。主要研究包括對臨床醫生、採購負責人和患者權益倡導團體進行結構化訪談，以收集他們在實際臨床環境中使用醫療設備的便利性、融入臨床工作流程以及用藥依從性挑戰方面的直接經驗。基於這些訪談，研究人員進行了主題分析，以突出與連接性、管理柔軟性和看護者支持相關的通用挑戰和改進領域。

結合互通技術、營運靈活性和有針對性的證據產生的整合策略將決定液體療法的長期成功。

持續皮下胰島素輸注療法正處於一個充滿巨大潛力和複雜性的轉折點，技術成熟度、變革性護理模式和全球政策趨勢在此交匯。兼具穩健安全設計、無縫資料整合和人性化的易用性的設備將能夠更有效地滿足臨床醫生和患者的期望。同時，供應鏈的靈活性和監管方面的前瞻性對於在不斷變化的貿易和合規環境中保持競爭力至關重要，同時也能確保患者獲得治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：持續皮下胰島素輸注市場：依產品類型分類

  • 傳統的
    • 電子泵浦
    • 機械幫浦
  • 修補

第9章：按胰島素類型分類的持續性皮下胰島素輸注市場

  • 快速起效的類似物
  • 標準胰島素
  • 短效

第10章：持續皮下胰島素輸注市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第11章：持續皮下胰島素輸注市場：依最終用戶分類

  • 門診治療
  • 居家醫療
  • 醫院

第12章：持續皮下胰島素輸注市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：持續皮下胰島素輸注市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：持續皮下胰島素輸注市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國持續皮下胰島素輸注市場

第16章：中國持續皮下胰島素輸注市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Bigfoot Biomedical, Inc.
  • BPL Medical Technologies Private Limited
  • CeQur SA
  • F. Hoffmann-La Roche Ltd.
  • Forbion
  • Fresenius SE & Co. KGaA
  • Insulet Corporation
  • MannKind Corporation
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Pharmasense AG
  • Sanofi SA
  • Shinmyung Mediyes CO., LTD.
  • SOOIL Developments Co., Ltd.
  • Tandem Diabetes Care, Inc.
  • Terumo Group
  • Ypsomed AG
Product Code: MRR-A339DAEFA756

The Continuous Subcutaneous Insulin Infusion Market was valued at USD 3.41 billion in 2025 and is projected to grow to USD 3.81 billion in 2026, with a CAGR of 12.62%, reaching USD 7.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.41 billion
Estimated Year [2026] USD 3.81 billion
Forecast Year [2032] USD 7.84 billion
CAGR (%) 12.62%

How evolving clinical priorities and technology convergence are reshaping continuous insulin delivery toward patient-centered, connected therapy solutions

Continuous subcutaneous insulin infusion has evolved from a niche clinical intervention to a central modality in diabetes care, driven by both technological innovation and shifting care paradigms. Modern systems prioritize patient-centric features such as usability, integration with glucose monitoring tools, and ergonomic design. As clinicians emphasize personalized glycemic management, device developers respond with refined delivery mechanisms, intuitive user interfaces, and connectivity that supports remote monitoring and telehealth workflows.

Clinical guidelines increasingly recognize the role of pump therapy in improving glycemic stability for selected patient populations, and payer perspectives are adapting to evidence that links improved outcomes with reduced acute complications. Meanwhile, regulatory pathways have matured to accommodate iterative improvements in hardware and software, which allows manufacturers to deploy enhancements without reworking entire device platforms. These developments encourage a steady cadence of product refreshes and software-driven feature additions.

At the same time, patient expectations have shifted toward minimally intrusive devices that fit diverse lifestyles. Consequently, design emphasis has moved toward smaller form factors, discreet wearability, and simplified maintenance. In parallel, data analytics and interoperability features have become differentiators, enabling caregivers and care teams to interpret longitudinal glucose data and optimize therapy. Taken together, these forces are shaping a landscape where clinical effectiveness, user experience, and system connectivity determine competitive positioning.

Emerging digital integration, adaptive control algorithms, and supply chain modernization are rapidly transforming insulin pump therapy and care delivery models

Recent transformative shifts in continuous subcutaneous insulin infusion reflect a convergence of digital health, device miniaturization, and integrated care models that together redefine therapeutic expectations. Advances in sensor accuracy and algorithm sophistication enable smarter insulin delivery decisions that adapt to real-world variability in activity, meals, and stress. As a result, product roadmaps prioritize closed-loop compatibility, adaptive control strategies, and secure data exchange to support longitudinal care management.

Simultaneously, manufacturing and supply chain strategies are evolving to accommodate higher integration of electronics and software, prompting collaborative partnerships between established device manufacturers, semiconductor suppliers, and software specialists. This trend reduces time to market for complex assemblies and drives innovation in cost and component sourcing. Regulatory bodies are responding by refining guidance on software validation and cybersecurity to ensure safety without unduly hindering iterative innovation.

In parallel, reimbursement models and care delivery frameworks are gradually aligning to support home-based chronic disease management, encouraging providers to prescribe devices that enable remote monitoring and reduce inpatient utilization. Patient advocacy and education initiatives further spur adoption by demystifying device use and emphasizing quality-of-life benefits. Collectively, these shifts create a dynamic environment where cross-functional integration, evidence generation, and user-centered design determine long-term success.

Trade policy shifts in 2025 compel agile supply chain redesign, tariff mitigation tactics, and strategic commercial responses across insulin delivery stakeholders

The introduction of tariffs and adjusted trade policies in 2025 has clear operational and strategic implications for manufacturers, distributors, and healthcare providers involved in continuous subcutaneous insulin infusion. Procurement teams must reassess sourcing strategies to mitigate increased landed costs and potential lead-time variability. In response, firms evaluate alternative manufacturing footprints, consider nearshoring components, and renegotiate supplier contracts to distribute tariff exposure across supply chain tiers.

Beyond procurement, regulatory and compliance functions are recalibrating documentation and customs classifications to ensure accurate duty treatment and to exploit available preferential trade programs where applicable. Firms with modular supply chains and diversified supplier pools demonstrate greater resilience, while those reliant on a narrow set of overseas suppliers face heightened vulnerability to price volatility. Consequently, strategic planning now integrates scenario modeling that examines the operational implications of tariff fluctuations on production schedules and customer pricing.

Commercial teams confront the challenge of preserving market access and affordability for patients, balancing cost absorption against the risk of reduced demand sensitivity. As transitional strategies, stakeholders pursue targeted cost optimization initiatives, incremental pricing adjustments, and enhanced service offerings to sustain value propositions. In short, trade policy shifts underscore the importance of agile supply chain design, proactive regulatory engagement, and strategic commercial planning to maintain continuity and competitiveness.

Multi-dimensional segmentation across product architecture, insulin formulations, patient age cohorts, and care settings reveals differentiated adoption drivers and design imperatives

A rigorous segmentation lens clarifies how product design, insulin formulations, patient demographics, and care settings shape adoption and user experience across continuous infusion solutions. When analyzed by product type, distinctions between Conventional systems and Patch-based devices influence clinical suitability and patient preference; Conventional options further differentiate into electronics-based pumps and mechanical pumps, with electronics-driven platforms offering programmable delivery patterns, connectivity, and advanced safety interlocks while mechanical pumps emphasize simplicity and durability for specific use cases. Regarding insulin type, choices among rapid-acting analogs, regular insulin, and short-acting formulations affect pharmacodynamic profiles and dosing algorithms, informing both device programming and clinical titration strategies.

Age group segmentation highlights divergent needs across adult, geriatric, and pediatric cohorts: adults often prioritize lifestyle compatibility and discrete connectivity, geriatric populations require simplified interfaces and robust safety features to mitigate cognitive or dexterity limitations, and pediatric care demands highly adaptable dosing ranges, caregiver control features, and educational supports. Finally, end-user perspectives spanning ambulatory care, homecare, and hospitals reveal distinct procurement drivers and operational requirements; ambulatory settings emphasize portability and data sharing for outpatient management, homecare focuses on ease of use and long-term adherence supports, and hospital environments prioritize interoperability with electronic health records, sterile supply protocols, and acute glycemic control reliability. Together, these segmentation dimensions inform product development, clinical positioning, and commercialization strategies that align technological capabilities with diverse real-world needs.

Regional differentiation across the Americas, Europe Middle East & Africa, and Asia-Pacific demands tailored regulatory, reimbursement, and commercialization approaches

Regional dynamics exert a powerful influence on adoption pathways, reimbursement frameworks, and infrastructure readiness for continuous infusion technologies. In the Americas, healthcare systems and payer models create varied uptake scenarios, with pockets of advanced adoption where integrated care networks and diabetes management programs prioritize connected solutions. Consequently, manufacturers orient clinical engagement and distribution strategies to align with regional reimbursement policies and specialist training programs.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse healthcare access levels create both challenges and opportunities. Some European markets emphasize rigorous clinical evidence and data privacy compliance, while markets across the Middle East and Africa offer growth opportunities tied to public health initiatives and infrastructure investments. Manufacturers must therefore adopt differentiated market-entry strategies that respect local regulatory requirements and leverage partnership channels for clinician education.

Asia-Pacific presents a complex mix of rapid urbanization, expanding private healthcare provision, and varied regulatory frameworks that encourage innovation adoption in urban centers while rural access remains a strategic consideration. Across all regions, supply chain reliability, local regulatory harmonization, and culturally appropriate patient education programs determine the pace of adoption. As such, regional strategies must integrate tailored value propositions, local stakeholder engagement, and flexible commercial models to navigate distinct healthcare landscapes effectively.

Competitive landscape shaped by legacy device manufacturers, software-first entrants, and outcome-driven service models that redefine value across therapy lifecycles

Competitive dynamics reflect a blend of established medical device firms, emerging technology entrants, and specialized component suppliers collaborating to advance continuous infusion capabilities. Incumbent manufacturers leverage deep clinical relationships, regulatory experience, and broad distribution networks to maintain market presence, while newer entrants frequently emphasize software innovation, user experience, and niche form factors to capture specific patient segments. Strategic alliances between device makers and digital health vendors accelerate feature integration, particularly around closed-loop compatibility and data analytics services.

Investments in intellectual property around infusion algorithms, sensor interoperability, and cybersecurity represent strategic priorities, as stakeholders seek to protect differentiating features while enabling controlled interoperability. At the same time, service-oriented business models-such as bundled devices with remote monitoring subscriptions or integrated training and adherence programs-gain traction, creating recurring revenue streams and enhanced patient engagement. Procurement and hospital sourcing teams increasingly evaluate total cost of ownership alongside clinical outcomes, which encourages vendors to demonstrate longitudinal value through real-world evidence and post-market studies.

Looking ahead, competitive advantage will accrue to organizations that combine regulatory agility, robust quality and supply systems, and a clear product-service strategy that supports clinicians and patients through the entire therapy lifecycle. Collaboration with payers, providers, and patient groups will further distinguish vendors able to translate technical features into measurable care improvements.

Prioritize interoperability, supply diversification, real-world evidence, and human-centered design to strengthen resilience and accelerate adoption across care settings

Industry leaders should prioritize a strategic agenda that aligns product innovation with clinical integration, supply chain resilience, and payer engagement to preserve sustainability and accelerate adoption. First, invest in interoperable platforms and validated algorithms that enable meaningful data exchange with glucose monitoring systems and electronic health records; this foundation supports clinician workflows and enhances the clinical utility of therapy data. Second, diversify manufacturing and sourcing strategies to reduce exposure to trade policy volatility and component shortages while accelerating time to recovery in the event of disruption.

Third, build evidence-generation programs that go beyond controlled trials to include real-world studies, health economic analyses, and patient-reported outcomes; these data strengthen reimbursement conversations and inform iterative design improvements. Fourth, tailor commercial models to regional payer landscapes and end-user needs by offering flexible purchasing options, service bundles, and clinician training that lower barriers to adoption. Fifth, embed human-centered design principles to ensure devices meet the cognitive, sensory, and lifestyle needs of varied age groups, thereby improving adherence and satisfaction.

Finally, cultivate multi-stakeholder partnerships spanning clinicians, payers, patient advocacy groups, and technology partners to co-create solutions that align clinical efficacy with practical implementation. By executing this multipronged strategy, industry leaders will enhance resilience, foster differentiated value, and deliver improved outcomes for patients and care teams alike.

A transparent mixed-methods research framework combining stakeholder interviews, clinical literature synthesis, and supply chain analysis to produce actionable device and commercial insights

The research approach integrates qualitative and quantitative methods to ensure comprehensive insight into device performance, stakeholder perspectives, and operational constraints. Primary research included structured interviews with clinicians, procurement officers, and patient advocates to capture firsthand experience with device usability, clinical workflow integration, and real-world adherence challenges. These conversations informed thematic analysis that highlights common pain points and opportunity areas related to connectivity, dosing flexibility, and caregiver support.

Secondary research synthesized publicly available regulatory guidance, clinical literature, and technical standards to contextualize product design and approval considerations. Where applicable, technical white papers and peer-reviewed clinical studies supported assessments of algorithmic approaches and safety considerations. Supply chain and trade policy impacts were analyzed using trade flow data, procurement publications, and supplier disclosures to develop a pragmatic view of operational vulnerabilities and mitigation levers.

Finally, cross-validation exercises reconciled primary insights with secondary sources to increase confidence in thematic findings and recommendations. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, and it supports actionable conclusions for product development, commercialization, and strategic planning while acknowledging regional variability and evolving regulatory expectations.

An integrated strategy combining interoperable technology, operational agility, and targeted evidence generation will determine long-term success in infusion therapy

Continuous subcutaneous insulin infusion stands at an inflection point where technological maturation, shifting care models, and global policy dynamics converge to create both promise and complexity. Devices that marry robust safety engineering with seamless data integration and human-centered usability will meet clinician and patient expectations more effectively. At the same time, supply chain agility and regulatory foresight are crucial to navigate evolving trade and compliance landscapes without interrupting patient access.

The interplay between device form factor, insulin pharmacology, patient age-related needs, and care setting requirements underscores the importance of nuanced product portfolios and targeted clinical engagement. Moreover, competitive advantage will favor organizations that can translate technical differentiation into verifiable clinical and economic benefits. In conclusion, stakeholders who adopt an integrated strategy-combining interoperable technology, diversified operations, strong evidence generation, and tailored regional approaches-will be best positioned to deliver meaningful improvements in diabetes management and to sustain long-term growth in a dynamic therapeutic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Subcutaneous Insulin Infusion Market, by Product Type

  • 8.1. Conventional
    • 8.1.1. Electronics Based Pumps
    • 8.1.2. Mechanical Pumps
  • 8.2. Patch

9. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type

  • 9.1. Rapid Acting Analog
  • 9.2. Regular Insulin
  • 9.3. Short Acting

10. Continuous Subcutaneous Insulin Infusion Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Continuous Subcutaneous Insulin Infusion Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Homecare
  • 11.3. Hospitals

12. Continuous Subcutaneous Insulin Infusion Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Continuous Subcutaneous Insulin Infusion Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Continuous Subcutaneous Insulin Infusion Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Continuous Subcutaneous Insulin Infusion Market

16. China Continuous Subcutaneous Insulin Infusion Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. B. Braun SE
  • 17.6. Baxter International, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bigfoot Biomedical, Inc.
  • 17.9. BPL Medical Technologies Private Limited
  • 17.10. CeQur SA
  • 17.11. F. Hoffmann-La Roche Ltd.
  • 17.12. Forbion
  • 17.13. Fresenius SE & Co. KGaA
  • 17.14. Insulet Corporation
  • 17.15. MannKind Corporation
  • 17.16. Medtronic PLC
  • 17.17. MicroPort Scientific Corporation
  • 17.18. Nipro Corporation
  • 17.19. Pharmasense AG
  • 17.20. Sanofi S.A.
  • 17.21. Shinmyung Mediyes CO., LTD.
  • 17.22. SOOIL Developments Co., Ltd.
  • 17.23. Tandem Diabetes Care, Inc.
  • 17.24. Terumo Group
  • 17.25. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 105. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 123. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 129. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)